Werewolf Therapeutics
HOWL----
Werewolf Therapeutics (HOWL)
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the tr...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Werewolf Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 29, 2026Price forecast
$7.001539.34%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 2 days ago, 12:05 PM
12 Health Care Stocks Moving In Friday's Intraday Session
- PUBT · Jul 8 at 04:34 PM
Werewolf Therapeutics director Luke Evnin reports disposal of common shares worth $44,155.83
- PUBT · Jun 29 at 06:08 PM
Werewolf Therapeutics director Luke Evnin disposes of 157,084 common shares for $47,125.2
- PUBT · Jun 22 at 06:00 PM
RA Capital Management disposes of Werewolf Therapeutics shares worth $145,069
- Market Beat · May 21 at 07:24 AM
Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
- nasdaq · May 8 at 05:55 AM
Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz
